Back to Search VC Home Page
Venture Capital Search Engine
search over 1,000 Venture Capital related sites
Keywords about VC:  

CDIB Ventures

1.CDIB Ventures: Contact   (99%):
Qualified companies that fit CDIB Ventures’ investment parameters should submit a 1-2 page Executive Summary via U.S. mail, fax or e-mail. CDIB Ventures 3945 Freedom Circle Suite 270 Santa Clara, CA 95054 (phone) 408-235-8688 (fax) 408-235-8816 Directions Information ( info@cdibventures.com ) H...
2.CDIB Ventures: Background   (99%):
CDIB Ventures is a subsidiary of China Development Industrial Bank (CDIB). The firm was established in October 1997 in Silicon Valley to oversee CDIB's initial North American venture capital fund and to expand its investment activities. In addition to financial resources, CDIB Ventures receives full...
3.CDIB Ventures: Philosophy   (91%):
"People Capital": The Key to Global Success Every company needs funding to build a business. But new economy businesses need financial backing and the contacts to open doors worldwide. CDIB Ventures' vast network of global contacts can provide entrepreneurs with these vital connections. Wi...
4.CDIB Ventures   (77%):
ComVentures Acquires Interest in Axesstel CCPU Closed $15 Million in New Venture Financing DoOnGo Renamed to Innopath and Extends its Reach in Asia/Pacific with New Office in Korea Kasenna Closes $15 Million in New Funding Today's private and public companies have a truly global vision. They're crea...
5.CDIB Ventures   (77%):
ComVentures Acquires Interest in Axesstel CCPU Closed $15 Million in New Venture Financing DoOnGo Renamed to Innopath and Extends its Reach in Asia/Pacific with New Office in Korea Kasenna Closes $15 Million in New Funding Today's private and public companies have a truly global vision. They're crea...
6.CDIB Ventures: Approach   (76%):
Careful Investing, Impressive Returns The CDIB Ventures approach to VC investment is grounded in comprehensive knowledge of the industry and years of expertise in business and finance. Our objective is to achieve superior returns by investing in a carefully selected portfolio of companies. Investmen...
7.CDIB Ventures: Directions to CDIB - Santa Clara   (74%):
Directions to CDIB Ventures' Santa Clara Office CDIB Ventures’ California office is located in Santa Clara -- in the heart of Silicon Valley -- only a 10-minute drive from San Jose Airport and 45 minutes from San Francisco International Airport (without traffic). From San Francisco and SFO Inte...
8.Easton Capital Investment Group::Transave, Inc   (74%):
Transave, Inc. Transave is a biotechnology company that treats pulmonary diseases via their proprietary inhaled lipid complexed/liposomal drug delivery technology. The Company's SLIT technology enables both sustained release and enhanced targeting of therapeutic compounds to the diseased areas of th...
9.China Development Industrial Bank Ventures   (74%):
CDIB Ventures is a wholly owned subsidiary of China Development Industrial Bank (CDIB), a leading financial institution in Taiwan. Established more than 40 years ago, CDIB is the country s leading institutional investor, as well as a top investment bank. CDIB Ventures was established in Silicon Val...
10.CDIB Ventures: Team   (64%):
Full-Scale Experience for "Big Picture" Investing While the global new economy is brimming with opportunity, it is not free of challenges. The CDIB Ventures team has the proven ability to identify sound opportunities that can provide significant returns to entrepreneurs and investors. Our ...
11.ATIG Strategic Partners   (57%):
Austin Ventures Austin Ventures is one of the top decile venture capital firms in the US and has been investing to build valuable companies since 1979 in the US with a focus on Texas. With $2.4 billion under management, Austin Ventures is the most active venture capital firm in Texas, and one of th...
12.Easton Capital Investment Group::Renovis, Inc.   (55%):
Renovis, Inc. Renovis (NASD:RNVS) is a biopharmaceutical company that discovers and develops drugs to address neurological conditions and neuroinflammatory disorders. The Company has several drug candidates in development, including Cerovive, a Phase III drug for acute ischemic stroke that is partne...
13.Intelligent Capital - Relationships   (45%):
Intelligent Capital's Relationships Include Enterprise Software Information Security Networking & Communications Semiconductors Venture Capital Venture Capital Acer Tech Ventures Advent International Allegis Capital Alloy Ventures Alta Partners Altos Ventures Angel Investors Apax Partners Athen...
14.Welcome to Academy Funds   (40%):
Academy Funds (Academy Ventures) is a family of venture capital funds focused on achieving outstanding investment returns in seed and early-stage companies. The following is a partial list of companies/institutions that have co-invested in and/or partnered with Academy portfolio companies: Advent V...
15.InterWest Partners - Investing in Information Technology & Life Sciences   (35%):
InterWest News InterWest Releases Portfolio News Portfolio Releases Events [ Portfolio News - Main ] Corgentech IPO Boosted To 6M Shares, Trades up 33.75% By VentureWire Staff Reporters 2/13/2004 Corgentech's initial public offering was increased from 5 million to 6 million shares and priced at $16....
16.BA Venture Partners - News: Portfolio News   (33%):
BAVP News Portfolio News Events Somaxon Files IPO To Raise Up To $86.25M In Common Stock By VentureWire Staff Reporters VenutreWire: October 10th, 2005 Psychiatric drug developer Somaxon Pharmaceuticals Inc. Friday filed for an initial public offering to sell up to $86.25 million in common stock, in...
17.In-Q-Tel — Investments   (33%):
Arizona State University Candera Open GIS Consortium SAIC SRA Verity Nanosys, Inc. is an advanced technology company, leading the burgeoning nanotechnology industry through the development of nano-enabled systems. These systems incorporate novel and patent-protected nanostructures that integrate fun...
18.In-Q-Tel — Investments   (33%):
Arizona State University Candera Open GIS Consortium SAIC SRA Verity Nanosys, Inc. is an advanced technology company, leading the burgeoning nanotechnology industry through the development of nano-enabled systems. These systems incorporate novel and patent-protected nanostructures that integrate fun...
19.Acorda :: Current Investors   (25%):
Acorda Therapeutics is a privately held biotechnology company devoted to developing therapies for individuals with spinal cord injury, multiple sclerosis, and related disorders of the nervous system. Since its inception in 1995, Acorda has raised over $140 million through a combination of individua...
20.Flagship Ventures   (23%):
Flagship & Portfolio Company News Archives 2003 2002 CombinatoRx Licenses CRx-026 Territory Right to HenKan Partnership Accelerates Development and Commercialization of CRx-026 in Taiwan, China and South Korea BOSTON, MA and TAIPEI, TAIWAN -- July 18, 2005 - CombinatoRx, Incorporated, a privately he...

Page: 1   2   3   4   5   6   7   8   9   10   11   12   13   14   15   16   17   18   19   20  

VC Directory: A   B   C   D   E   F   G   H   I   J   K   L   M   N   O   P   Q   R   S   T   U   V   W   X   Y   Z   Others